Angiogenic growth factors in tissue homogenates of HNSCC: Expression pattern, prognostic relevance, and interrelationships

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1210-1218

  Montag, Michael ^a,b   Dyckhoff, Gerhard ^a   Lohr, Jennifer ^a   Helmke, Burkhard M ^a,c   Herrmann, Eva ^b   Plinkert, Peter K ^a   Herold Mende, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Elbe Kliniken   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; VASCULOTROPIN A; VASCULOTROPIN D;

ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GRADING; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MICROVESSEL DENSITY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; TISSUE HOMOGENATE; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INDUCING AGENTS; CARCINOMA, SQUAMOUS CELL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 67449098380     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01158.x     Document Type: Article

References (45)

1. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: A focus on human papillomavirus. J Dent Res 2007; 86: 104-14.
2. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5: 127-35.
3. Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 2004; 57: 595-602.
4. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003; 63: 1920-6.
5. St John MA, Abemayor E, Wong DT. Recent new approaches to the treatment of head and neck cancer. Anti-Cancer Drugs 2006; 17: 365-75.
6. Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 2006; 6: 1195-203.
7. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
8. Folkman J. Tumor angiogensis: Role in regulation of tumor growth. The Symp Soc for Dev Biol Soc for Dev Biol 1974; 30: 43-52.
9. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-47.
10. BergersG, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
11. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003; 106: 34-44.
12. Gospodarowicz D, Cheng J. Growth of myoblasts in lipoprotein-supplemented, serum-free medium: Regulation of proliferation by acidic and basic fibroblast growth factor. In Vitro Cell Dev Biol 1987; 23: 507-14.
13. Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res 1997; 17: 2249-52.
14. Cao R, Brakenhielm E, Pawliuk R et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9: 604-13.
15. Strauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): Possible link between angiogenesis and immune tolerance. Med Sci Monit 2005; 11: BR280-92.
16. Vasvari GP, Dyckhoff G, Kashfi F et al. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer2007; 121: 1697-704.
17. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 3305-13.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
19. Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629-41.
20. Matsumoto K, Matsumoto K, Nakamura T, Kramer RH. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994; 269: 31807-13.
21. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
22. Lutsenko SV, Kiselev SM, Severin SE. Molecular mechanisms of tumor angiogenesis. Biochemistry (Mosc) 2003; 68: 286-300.
23. Tabone MD, Landman-Parker J, Arcil B et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001; 7: 538-43.
24. Szabo S, Sandor Z. The diagnostic and prognostic value of tumor angiogenesis. Eur J Surg Suppl 1998: 99-103.
25. Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998; 108: 1413-7.
26. Kim CH, Moon SK, Bae JH et al. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006; 126: 88-94.
27. Alexandrakis MG, Passam FH, Pappa CA et al. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes. Correlation with Bone Marrow Microvascular Density Int J Immunopathol Pharmacol 2005; 18: 287-95.
28. Bussolino F, Wang JM, Defilippi P et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471-3.
29. Bussolino F, Ziche M, Wang JM et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991; 87: 986-95.
30. Tsuzuki H, Fujieda S, Sunaga H, Noda I, Saito H. Expression of granulocyte colony-stimulating factor receptor correlates with prognosis in oral and mesopharyngeal carcinoma. Cancer Res 1998; 58: 794-800.
31. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006; 66: 8026-36.
32. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2005: 1-7.
33. Tse GM, Chan AW, Yu KH et al. Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol 2007; 14: 3558-65.
34. Rosenthal E, McCrory A, Talbert M, Young G, Murphy-Ullrich J, Gladson C. Elevated expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol Carcinog 2004; 40: 116-21.
35. Dirnhofer S, Zimpfer A, Went P. [The diagnostic and predictive role of kit (CD117)]. Therapeutische Umschau 2006; 63: 273-8.
36. Gross DJ, Munter G, Bitan M et al. The role imatinib mesylate (Glivec) for treatment patients with malignant endocrine tumors positive for C-Kit PDGF-R. Endocrine-Related Cancer 2006; 13: 535-40.
37. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001; 33: 451-5.
38. Herold-Mende C, Steiner HH, Andl T et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 1999; 79: 1573-82.
39. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006; 17: 141-6.
40. Vellenga E, Rambaldi A, Ernst TJ, Ostapovicz D, Griffin JD. Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood 1988; 71: 1529-32.
41. Shikada Y, Yonemitsu Y, Koga T et al. Platelet-derived growth factor-AA is essential autocrine regulator vascular endothelial growth factor expression non-small cell lung carcinomas. Cancer Res 2005; 65: 7241-8.
42. Magnano M, Bongioannini G, Lerda W et al. Lymphnode metastasis in head and neck squamous cells carcinoma: Multivariate analysis of prognostic variables. J Exp Clin Cancer Res 1999; 18: 79-83.
43. Singh B, Li R, Xu L et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002; 24: 437-42.
44. Gotte K, Tremmel SC, Popp S et al. Intratumoral genomic heterogeneity in advanced head and neck cancer detected by comparative genomic hybridization. Adv Oto-Rhino-Laryngology 2005; 62: 38-48.
45. Grosbach AB. Carcinoma of unknown primary site: A clinical enigma. Arch Intern Med 1982; 142: 357-9.